Almac reports record financial results, reinvests all profits to support growth

Fueled by a more than £500 million global capital investment program, pharmaceutical development and manufacturing organization Almac Group on Tuesday announced record financial results with revenue, profit, and employee numbers at their highest levels to date.

The Craigavon, Northern Ireland-headquartered company reported that revenue rose to £1.1 billion for the year ending September 30, 2025, up £71.9 million (7%) compared to 2024, while pre-tax profit jumped by 16% to £138.9 million — compared with £119.3 million in the previous year — and Almac’s global workforce grew to more than 7,900 employees, a 6% increase over the same period.

During the recently completed financial year, Almac said it supported the development and ongoing commercial supply of hundreds of drugs across more than 20 therapeutic areas, including cardiology, gene therapy, immunology, neurology, and oncology.

“These results reflect another successful year for Almac and demonstrate the resilience of our long-term growth strategy in a changing global environment,” CEO Alan Armstrong said in a statement. “As a privately owned company, we are proud to reinvest our profits to support our global clients, drive innovation and expand our capabilities.”

Almac is reinvesting all its profits back into the company to support long-term growth, according to the announcement, which noted the latest financial results mark the fifth year of Almac’s £500 million-plus global capital investment program that was first announced in November 2021. Since then, the company has increased its global workforce by more than 2,000 employees, with more than half of the new roles created in Northern Ireland.

Long-term investment

Almac’s long-term investment program continues to drive its expansion, the company said, calling out capital expenditures across diagnostic and pharmaceutical development and manufacturing, clinical production and distribution, as well as commercial manufacturing and packaging, global cold chain infrastructure, and analytical services.

Almac Sciences, part of Almac Group, announced in March 2026 the launch of current Good Manufacturing Practice (cGMP)-compliant flow high-pressure hydrogenation to support clinical and commercial active pharmaceutical ingredient (API) manufacturing. The capability is meant to enable hydrogenation under continuous flow conditions at pressures up to 100 bar and temperatures up to 300°C, providing improved control over temperature, pressure, and mixing,

In November 2025, Almac announced a multi-million-pound expansion at its site in Singapore, marking a decade of operations in the Asian country. The investment, made by Almac Clinical Services, is part of the company’s long-term commitment to expand warehouse capacity in Singapore and increase regional clinical supply management expertise to support customer demand. 

In August, Almac opened new GMP-qualified analytical stability chambers and office space at its U.S. headquarters in Souderton, Pennsylvania. The $2 million investment expands its analytical capacity in response to increased demand for global stability programs, according to the company.

In July, Almac Clinical Services completed a multi-million-pound expansion of its cold chain infrastructure at its global headquarters. The investment included a newly built ultra-low temperature facility that has tripled the site’s secondary packaging capacity for -15°C to -25°C products and doubled its ULT storage capacity (-60°C to -80°C). 

Almac’s five-year growth strategy has included the quadrupling of dedicated -20°C capacity, expansion of secondary cold chain packaging capabilities, and enhanced temperature-controlled clinical supply services, according to the company.

Early in 2025, Almac opened an $84 million, 100,000-square-foot commercial manufacturing facility for Almac Pharma Services at its global headquarters in Northern Ireland.